Toshiaki Saeki

Toshiaki Saeki

Auto-generated profile, based on publicly available information

Toshiaki Saeki

Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
AAAya Asano
Aya Asano
SUSHIGETO UEDA
SHIGETO UEDA
IKIchiei Kuji
Ichiei Kuji
TYTomohiko Yamane
Tomohiko Yamane
HTHideki Takeuchi
Hideki Takeuchi
TSToshiaki Saeki
Toshiaki Saeki
Hypoxia is a key driver of cancer progression. We evaluated the prognostic impact of 18F-fluoromisonidazole (FMISO) prior to treatment in patients with breast cancer. Forty-four patients with stage II/III primary breast cancer underwent positron emission tomography/computed with 18F-fluorodeoxyglucose (FDG-PET/CT) and FMISO. After measurement by FDG-PET/CT, the tissue-to-blood ratio (TBR) was obtained using FMISO-PET/CT. FMISO-TBR was compared for correlation with clinicopathological factors, disease-free survival (DFS), and overall survival (OS). Multiplex cytokines were analyzed for the correlation of FMISO-TBR. Tumors with higher nuclear grade and negativities of estrogen receptor (ER) and progesterone receptor had significantly higher FMISO-TBR than other tumors. Kaplan-Meier survival curves showed that patients with a higher FMISO-TBR (cutoff, 1.48) had a poorer prognosis of DFS (p = 0.0007) and OS (p = 0.04) than those with a lower FMISO-TBR. Multivariate analysis indicated that higher FMISO-TBR and ER negativity were independent predictors of shorter DFS (p = 0.01 and 0.03). Higher FMISO-TBR was associated with higher plasma levels of angiogenic hypoxic markers such as vascular endothelial growth factor, transforming growth factor-α, and interleukin 8. FMISO-PET/CT is useful for assessing the prognosis of patients with breast cancer, but it should be stratified by ER status. UMIN Clinical Trials Registry, UMIN000006802 . Registered on 1 December 2011.

13 March 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KMKoji Matsumoto
Koji Matsumoto
MTMasato Takahashi
Masato Takahashi
KSKazuhiko Sato
Kazuhiko Sato
AOAkihiko Osaki
Akihiko Osaki
TTToshimi Takano
Toshimi Takano
IKIchiei Kuji
Ichiei Kuji
Purpose: To investigate whether palonosetron is better than granisetron in preventing chemotherapy‐induced nausea and vomiting (CINV) in a three‐drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC‐based regimen).Patients and Methods: Chemo‐naive women with primary breast cancer were randomly administered either palonosetron 0.75 mg (day 1) or granisetron 1 mg (day 1) combined with dexamethasone (12 mg at day 1, 8 mg at day 2 and day 3) and Fos 150 mg (day 1) before receiving AC‐based regimen in a double‐blind study. The primary endpoint was the complete response (CR) rate of emesis in cycle 1 in the delayed phase. This was defined as neither vomiting nor rescue drug usage for emesis at >24‐120 hours after chemotherapy. Secondary endpoints were the CR in the acute/overall phase (0‐24/0‐120 hours, respectively, after chemotherapy), no nausea and vomiting, Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE), and safety.Results: From December 2012 to October 2014, 326 patients were treated and evaluated (164/162 evaluable patients in granisetron/palonosetron arm, respectively). The CR during the delayed phase was 60.4% in the granisetron regimen and 62.3% in the palonosetron regimen. The CR during acute phase (73.2% vs 75.9%, respectively) and the CR during overall phase (54.9% in both regimens) were very identical. A significantly higher number of patients in the palonosetron arm were free from nausea during the delayed phase (28% vs 40.1%; P = .029). Adverse events were also identical, although infusion site reactions (ISR) were higher (20.3%‐23.3%) than preceding studies in both regimens.Conclusion: In combination with dexamethasone and Fos, this study suggests that palonosetron is not better than granisetron in chemo‐naive patients with primary breast cancer receiving AC‐based regimen. Administration of Fos in peripheral veins after AC‐based regimen increased ISR.

17 June 2021 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
KMKazuo Matsuura
Kazuo Matsuura
IKIchiei Kuji
Ichiei Kuji
TTTakao Takahashi
Takao Takahashi
TTTomoaki Torigoe
Tomoaki Torigoe
KWKeisuke Watarai
Keisuke Watarai
THTakashi Hojyo
Takashi Hojyo
Bone‑modifying agents (BMAs), including bisphosphonate and anti‑receptor activator of NF‑κB ligand (RANKL) antibodies, are effective in treating bone metastases. The present study is a case report on the efficacy and side effects of long‑term treatment with zoledronic acid, a BMA, in a 57‑year‑old woman. The patient was diagnosed with concurrent stage IV triple‑negative breast cancer and stage II colon cancer. The patient experienced complete remission of both these cancers following chemotherapy, zoledronic acid treatment and irradiation for breast cancer and surgery for colon cancer. The patient received long‑term zoledronic acid treatment and has survived >7 years after her initial diagnosis. The patient subsequently reported bilateral hip pain that was diagnosed as osteonecrosis of the femoral head, after the presence of bone metastases was ruled out using magnetic resonance imaging. The patient underwent bilateral artificial hip joint replacements. After orthopedic surgery, the multiple distant metastases, including a brain metastasis, remained in complete remission. It is well established that BMAs, such as zoledronic acid, increase the risk of osteonecrosis of the jaw, but it is not well understood if they can increase this risk in other anatomical locations. The findings of the present case study suggested that while long‑term use of BMAs may be effective in managing bone metastases, it may increase the risk of osteonecrosis in anatomical locations other than the jaw.